Baclofen for Smoking Cessation in a Non-Psychiatric Population
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis for this study is that, in nicotine-dependent tobacco smokers,
baclofen will be superior to placebo for smoking abstinence measures.
The secondary hypothesis is that subjects assigned to the baclofen groups will exhibit higher
rates of medication compliance (i.e. take the medication as directed for the trial period)
than those in the placebo group.
The tertiary hypothesis is that baclofen will lead to significant reductions in tobacco
withdrawal and craving ratings as compared to placebo.